Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment
November 15, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Bexsero, Trumenba, Bexsero (MenB)
Synonyms :
Meningococcal group B vaccine
Class :
Bacterial vaccine, inactivated
Brand Name :
Bexsero, Trumenba, Bexsero (MenB)
Synonyms :
Meningococcal group B vaccine
Class :
Bacterial vaccine, inactivated
Dosage Forms & StrengthsÂ
Intramuscular suspensionÂ
0.5ml/syringeÂ
Bexsero
0.5ml intramuscular as two doses administered one month apart
Trumenba
0.5ml intramuscular as two doses administered six months apart Or
0.5ml intramuscular as three doses administered at intervals of zero, one-two month, and 6months apart
Note: if the 2nd dose is given less than six months after the first dose, then the third dose must be given atleast a minimum of four months after the second dose
Indications: this vaccine is used to prevent infections caused by Neisseria meningitides serogroup B in adults who are at risk of meningococcal disease
Dosage Forms & StrengthsÂ
Intramuscular suspensionÂ
0.5ml/syringeÂ
Refer to adult dosingÂ
allogeneic processed thymus tissueÂ
meningococcal group B vaccine is known to interact with allogenic processed thymus tissue
the efficacy of the vaccine may be reduced
the efficacy of the vaccine may be reduced
the efficacy of the vaccine may be reduced
the efficacy of the vaccine may be reduced
the efficacy of the vaccine may be reduced
the efficacy of the vaccine may be reduced
the efficacy of the vaccine may be reduced
the efficacy of the vaccine may be reduced
the efficacy of the vaccine may be reduced
the efficacy of the vaccine may be reduced
the efficacy of the vaccine may be reduced
melphalan decreases the activity of meningococcal group B vaccine by antagonism.
when thiotepa and meningococcal group b vaccine combine, thiotepa decreases the effects of the vaccine by antagonism     
mercaptopurine on interacting with this vaccine decreases the vaccine's effect by antagonistic activity risk of infection increases on administering both the drugs simultaneously
dactinomycin diminish the therapeutic effects of the vaccine
the effect of the meningococcal vaccine is decreased by fluorouracil via pharmacodynamic antagonism
the effect of the meningococcal vaccine is decreased by fluorouracil due to pharmacodynamic antagonism
Actions and spectrum:Â
Protection against infection due to N.meningitidis is carried by meningococcal group B vaccineÂ
Frequency definedÂ
TrumenbaÂ
Fatigue (≥40%)Â
Pain in the joints (17-21.6%)Â
Headache ((≥35%)Â
Chills ((≥15%)Â
Pain at the site of injection ((≥85%)Â
Fever (≥1.1-6.4%)Â
BexseroÂ
Pain (83-90%)Â
Arthralgia (13-16%)Â
Duration (28-32%)Â
Nausea (18-19%)Â
Myalgia (16-19%)Â
Headache (33-34%)Â
Black Box Warning Â
Syncope is reported; ensure safety procedures to avoid injury due to fainting.Â
Contraindication/Caution:Â
Contraindication:Â
HypersensitivityÂ
Syncope
Pregnancy consideration:Â Â
Limited data availableÂ
Lactation:Â
Limited data available Â
Pregnancy category:Â Â
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus `in either the first or second trimester.Â
Category B: There was a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.  Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.  Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this category
Pharmacology:Â
The meningococcal group B vaccine is a vaccination designed to protect against Neisseria meningitidis serogroup B, a bacterium that can cause meningitis and other severe infections.Â
Pharmacodynamics:Â
The vaccine works by stimulating the immune system to produce an immune response against the specific components of the Neisseria meningitidis serogroup B bacteria.Â
Pharmacokinetics:Â
AbsorptionÂ
The meningococcal group B vaccine is typically administered through intramuscular injection. This route allows for efficient absorption of the vaccine components into the bloodstream.Â
Once injected, the vaccine’s antigens stimulate the immune system to produce an immune response.Â
DistributionÂ
The vaccine components are distributed throughout the body via the bloodstream.Â
MetabolismÂ
Do not undergo typical metabolic processes in the same way drugs do.Â
Elimination and excretionÂ
The vaccine components, once they have served their purpose in activating the immune system, are not excreted from the body in the same way drugs are.Â
Half-life:Â
Administration:Â
Utilizing a sterile needle connected to the given prefilled syringe, inject each 0.5 mL dose intramuscularly.Â
The upper arm’s deltoid muscle is the recommended injection site.Â
Don’t combine any vaccines in one syringe with another.Â
Patient information leafletÂ
Generic Name: meningococcal group B vaccine Â
Why do we use meningococcal group B vaccine?Â
The meningococcal group B vaccine is used to prevent invasive infections caused by Neisseria meningitidis serogroup B.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
